A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

This surgical "window of opportunity" trial is testing a drug called troriluzole in patients with recurrent glioblastoma — a fast-growing brain tumor — who are being planned for repeat surgery. Patients take the drug before surgery so researchers can measure its effect on tumor tissue and see if it targets a key pathway (glutamate signaling) that drives glioblastoma growth. **You may be eligible if...** - You are 18 or older with IDH wild-type glioblastoma (a specific type of aggressive brain tumor confirmed by genetic testing) - Your tumor has come back after prior radiation and/or chemotherapy (no more than 2 relapses) - You are a candidate for surgery and have good functional status (Karnofsky ≥60) - You have adequate blood counts, liver, and kidney function **You may NOT be eligible if...** - Your cancer has spread throughout the brain lining (leptomeningeal disease) or outside the brain - You have previously taken troriluzole or riluzole - You have significant heart or lung disease, active infection, or HIV/hepatitis B or C - You are pregnant or breastfeeding - You cannot swallow pills Talk to your doctor to see if this trial is right for you.